January 22, 2017 6:04 AM ET


Company Overview of REGiMMUNE Corporation

Company Overview

REGiMMUNE Corporation, a biotechnology company, engages in the discovery, development, and commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders. Its products include RGI-2001 for graft versus host disease (GvHD) associated with hematopoietic stem cell transplantation (HSCT) as a proof of concept; and RGI-3010, a immunetolenance inducing liposome encapsulating proinsulin designed to increase the number of regulatory T cells and tolerize the immune system to proinsulin, thereby turning off the self directed immune attack. The company was founded in 2006 and is headquartered in Tokyo, Japan. It has an additional office in Mountain Vie...

1-7-8 Kaigan

Tokyo Industry Trade Center 607 (6th Floor)


Tokyo,  105-0022


Founded in 2006


81 3 6809 2199

Key Executives for REGiMMUNE Corporation

Chief Executive Officer
Age: 50
Scientific Founder and Executive Chairman
Chief Development Officer and Senior Director
Compensation as of Fiscal Year 2016.

REGiMMUNE Corporation Key Developments

REGiMMUNE Corporation Announces Address Change

REGiMMUNE Corporation has moved its business to a new location. The new address is as follows: 35-3 Nihonbashi Hakozaki-cho BRICK GATE 5F Chuou-ku Tokyo 103-0015 Japan. Telephone numbers remain the same.

REGiMMUNE Announces Executive Changes

REGiMMMUNE announced that its Board of Directors has appointed Kenzo Kosuda as Chief Executive Officer effective July 1, 2016. Yasuyuki Ishii will assume the role of Executive Chairman on July 1, 2016, and will continue to serve as the Chairman of REGiMMUNE’s Board. Kenzo joined REGiMMUNE in 2013. He most recently served as REGiMMUNE’s executive vice president and CFO/COO. REGiMMMUNE also announced that Yasuyuki Ishii, currently President and CEO, will remain on the board and assume the role of Executive Chairman on June 15. He will devote his time to supporting Kenzo and expanding the applications of reVax technology as both inventor and evangelist. Yasuyuki Ishii has served as independent director of REGiMMMUNE since inception, in 2006 and as CEO from 2014.

REGiMMUNE Corporation Appoints Joseph Mccracken to its Board of Directors

REGiMMUNE Corporation announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives, and serves on the Board of Alkahest Inc., Genkyotex S.A., Savara Pharmaceuticals and Nexvet Biopharma. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities.

Similar Private Companies By Industry

Company Name Region
ACTGen, Inc. Asia
Amano Enzyme Inc. Asia
Ambicion Inc. Asia
ArBlast Co., Ltd. Asia
Argenes, Inc. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact REGiMMUNE Corporation, please visit www.regimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.